Vincristine impairs musculoskeletal development in pediatric mice.

ABSTRACT:

Background

Over 85% of children diagnosed with cancer now survive their disease, yet cancer and chemotherapy frequently associate with long-term health complications, including impaired musculoskeletal development. Despite high survival rates, there is limited research on how pediatric chemotherapy affects muscle and bone physiology. Vincristine, a vinca alkaloid chemotherapeutic, is widely used in pediatric oncology, but its systemic effects on the developing musculoskeletal system remain poorly understood. This study aimed to investigate the musculoskeletal consequences of vincristine in a pediatric mouse model.

Methods

Four-week-old male C57BL/6J mice were administered vincristine (1.5 mg/kg, intraperitoneally, twice weekly) or vehicle for five weeks. Body mass was monito

SUBMITTER: Jamnick NA 

PROVIDER: S-EPMC12625613 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature